The NSCLC curriculum includes an interactive, online activity in which learners follow two unique patient cases and participate in clinical decisions. Dr. Nasser Hanna will help learners navigate through these simulated patient settings, discussing best practices and approaches in the assessment and management of patients with NSCLC. Following the completion of the patient cases, learners will be provided customized recommendations for additional opportunities to earn CME credits. These additional accredited activities consist of 2 webcasts and 1 article. In addition, supplemental resources will be available to download and will include guidelines, peer-reviewed publications and patient education materials. Learners will have an opportunity to earn up to 2.0 AMA PRA Category 1 CreditsTM for completion of the curriculum.
The NSCLC Virtual Clinic is a unique opportunity for clinicians to participate in optimal treatment approaches practiced in clinic settings, and learn through interactive case-based experiences. This virtual learning environment allows the clinician to follow the patient throughout the full cycle of care and make clinical decisions which impact patient outcomes. Upon completion of the Virtual Clinic, a personalized education plan will be provided outlining opportunities for additional education. Supplemental activities will address selection of initial and maintenance therapies, and emerging therapies.
Release Date: 4/7/2015
Expiration Date: 4/7/2016
In the past few decades, lung cancer has evolved from an untreatable disease to one that has a number of novel therapeutic options for individualizing treatment. It is now understood that its classification is far more complex than the division into small cell and non-small cell lung cancer (NSCLC). With the tremendous increase in understanding of the biological mechanisms that underlie lung cancer development, there has followed identification of novel therapeutic targets, and, in a subset of patients, an ability to predict responsiveness to treatment. As the management of NSCLC continues to rapidly evolve, clinicians must remain up-to-date with available data to ensure that all patients receive proper care across all stages of their disease.
This educational activity is designed for medical oncologists, surgical oncologists, pathologists and pulmonologists.
Upon completion of this activity, participants will be able to:
>Additional educational resources will also be provided for further education/reference on this topic. Certificates will be immediately available for each component. For questions, contact Katie Hacias at 773.714.0705 x.159 or khacias@achlcme.org
>
>This activity was planned and implemented by Indiana University School of Medicine and the Academy for Continued Healthcare Learning (ACHL).
>Associate Professor of Medicine
Indiana University
Indianapolis, Indiana
>Associate Professor of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
>Program Director, Lung Cancer Research
SCRI-Sarah Cannon Research Institute
Medical Oncologist
Tennessee Oncology, PLLC
Nashville, Tennessee
Indiana University School of Medicine requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. Conflict resolution must occur prior to the CME/CE activity. Indiana University School of Medicine also requires participating faculty to disclose when unapproved/unlabeled uses of a product are discussed in a CME/CE activity.
This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. Indiana University School of Medicine requires the speaker to disclose that a product is not labeled for the use under discussion. The provider’s documentation of common practices that make the disclosure requirement known to faculty demonstrates compliance with ACCME guidelines.
The faculty members have provided the following disclosure information.
Nasser Hanna, MD (Chair):
Grant Support: Merck & Co., Inc.
David Spigel, MD (Faculty):
has no relevant financial relationships to disclose.
Lecia Sequist, MD, MPH (Faculty):
Consulting agreements: AstraZeneca; Boehringer Ingelheim Pharm Inc; Clovis; Genentech, Inc; Merrimack Pharmaceuticals; Novartis AG; Taiho Pharmaceutical Co., Ltd
Discussion of Off-Label, Investigational, or Experimental Drug Use: drugs and biologicals in chemotherapy regimens for non-small cell lung cancer.
ACHL and Indiana University School of Medicine staff members, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
Indiana University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Indiana University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Indiana University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
While they offer CME credits, these activities are not intended to provide extensive training or certification in the field.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
